Medicine and Dentistry
In Vitro
100%
Phosphotransferase Inhibitor
100%
Myeloma Cell
100%
Multiple Myeloma
100%
Cell Growth
100%
Bone Marrow Stromal Cell
85%
Interleukin 6
71%
Growth Inhibition
42%
Secretion (Process)
28%
Alternative Complement Pathway C3 C5 Convertase
28%
Nuclear Factor
28%
Tumor Necrosis Factor
28%
Melphalan
28%
Somatomedin C
28%
Dexamethasone
28%
Doxorubicin
28%
I Kappa B Kinase Inhibitor
28%
down Regulation
14%
Phosphotransferase
14%
Cytokine
14%
Multiple Myeloma Cell Line
14%
Combined Therapy
14%
Clinical Trial
14%
Cell Line
14%
Cell Adhesion
14%
Cytotoxicity
14%
Immunology and Microbiology
Myeloma Cell
100%
Multiple Myeloma
100%
Cell Growth
100%
Interleukin 6
71%
Growth Inhibition
42%
Complement Factor B
28%
Tumor Necrosis Factor
28%
Secretion (Process)
28%
Somatomedin C
28%
Dexamethasone
28%
Cell Adhesion
14%
Cytotoxicity
14%
down Regulation
14%
Mouse Model
14%
Cell Line
14%
Cytokine
14%
Multiple Myeloma Cell Line
14%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphotransferase Inhibitor
100%
Multiple Myeloma
100%
Interleukin 6
62%
Doxorubicin
25%
Alternative Complement Pathway C3 C5 Convertase
25%
Nuclear Factor
25%
Somatomedin C
25%
Tumor Necrosis Factor
25%
Dexamethasone
25%
Melphalan
25%
I Kappa B Kinase Inhibitor
25%
Mouse Model
12%
Clinical Trial
12%
Cytokine
12%
Phosphotransferase
12%
Cytotoxicity
12%